Nicotinamide (vitamin B3) is a precursor to nicotinamide adenine dinucleotide (NAD) and therefore plays an important role in supplying the energy required for metabolic processes throughout the human body. As such, it is a basic requirement for the growth of babies and children. Its deficiency can cause skin and digestive problems, insomnia, fatigue and loss of appetite. Nicotinamide is found in various foods, such as meat, fish, cereals, legumes, fruit, and nuts. Bacteria in the microbiome can also make nicotinamide from the amino acid tryptophan. Additionally, nicotinamide is a precursor to serotonin and melatonin.
In a previous randomized clinical trial (2) it was observed that applying a topical preparation containing 2% nicotinamide twice daily for eight weeks to the skin of atopic eczema patients reduced moisture loss and increased hydration of the layer. cornea (outer layer of the epidermis).
Atopic eczema causes redness of the skin due to inflammation (often in an allergic response). In the UK it is common in children and affects approximately 20% of the population (3). It is a condition that can be treated, but not cured. Nicotinamide supplements are believed to benefit skin health by increasing its moisture, elasticity, and overall structure through the synthesis of collagen and proteins that play an important role in the formation of keratin and filaggrin (a protein that binds keratin fibers. ) (4).
A new study (1) used data from 497 mother-child pairs from the Southampton Women's Survey (SWS), conducted in the United Kingdom, with a diagnosis of atopic eczema in the baby at 6 or 12 months. The level of nicotinamide was determined in the maternal blood samples. The results showed that a high level of nicotinamide in the mother's plasma during late pregnancy was associated with a lower prevalence of atopic eczema at 12 months, but not at 6 months. The authors state that this discrepancy "may reflect the heterogeneity of the etiology and pathogenesis of atopic eczema in early childhood." To date, no randomized clinical trials have been carried out with the administration of nicotinamide in the later stages of pregnancy in order to reduce the risk of atopic eczema in the baby, but this study seems to establish a solid foundation for it. The study does support the proposition that atopic eczema in babies originatesin utero .